Senores Pharma Q2 FY27 Revenue & EBITDA Hit Record Highs

Senores Pharmaceuticals Limited announced its unaudited consolidated financial results for the quarter and half-year ended September 30, 2026. The company reported record-high quarterly revenue and EBITDA for Q2 FY27, with total revenue reaching ₹192 crores, a 25% year-on-year increase, and EBITDA at ₹58 crores, up 38% year-on-year. For the half-year ended H1 FY27, total revenue grew 30% year-on-year to ₹373 crores, and EBITDA increased by 58% year-on-year to ₹111 crores. The company's Regulated Markets business showed strong momentum, with its ANDA portfolio nearly doubling. Senores Pharmaceuticals remains on track to achieve 30-40% revenue growth and 50-60% PAT growth in FY27.